Aventis Pharmaceuticals Inc.

Genzyme Corporation

Kwon Yon Musick

Philip M Weintraub

John G Jurcak

Shujaath Mehdi

Paul Robert Eastwood

Ramalinga M Dharanipragada

John Ziqi Jiang

Neil Moorcroft

Michael L Edwards

Matthieu Barrague

Timothy A Gillespy

Sungtaek Lim

Jack Roger Koehl

Yan Du

Nicholas J Hrib

Stefan Peukert

Michael R Angelastro

Gregory H Merriman

Bradford Hirth

Brian K Whiteley

Alexandre Gross

Jeffrey Stephen Sabol

Elina Makino

Joseph T Klein

Uwe Schwahn

Ashfaq Ahmad Parkar

Robert H Barker, Jr

Mary A Cromwell

David Stefany

Ashfaq Ahmed Parkar

John Jiang

Phillip Marvin Weintraub

James Pribish

Yong-Mi Choi

Mark Munson

Sachin Maniar

Paul R Eastwood

David W Stefany

Philip Marvin Weintraub

Timothy Alan Gillespy

Michael Louis Edwards

John Gerard Jurcak

Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

UDP glycosyltransferase inhibitors and methods of use

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)

The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R, R, R, R, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Substituted AZA-indoles as inhibitors of poly(ADP-ribose) polymerase (PARP)

Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK). 

Thienopyrazoles

The present invention relates to a series of substituted indole derivatives of the formula I: 

Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)

This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

Indole derivatives as interleukin-4 gene expression inhibitors

Growing community of inventors

Raritan, NJ, United States of America

Kwon Yon Musick